ZIVO — Zivo Bioscience Income Statement
0.000.00%
Last trade - 00:00- $70.69m
- $69.28m
- $0.16m
Annual income statement for Zivo Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.02 | 0 | 0 | 0.028 | 0.157 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | 0.012 | 0.049 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 8.58 | 8.52 | 8.73 | 7.29 | 13.5 |
| Operating Profit | -8.56 | -8.52 | -8.73 | -7.26 | -13.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -9.11 | -8.76 | -8.75 | -7.78 | -13.4 |
| Net Income After Taxes | -9.11 | -8.76 | -8.75 | -7.78 | -13.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -9.11 | -8.76 | -8.75 | -7.78 | -13.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -9.11 | -8.76 | -8.75 | -7.78 | -13.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -10.8 | -6.98 | -5.57 | -4.6 | -4.23 |